Ardelyx names new VP, CSO
This article was originally published in Scrip
Executive Summary
Ardelyx, a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, has appointed Dr Jeremy S Caldwell executive vice-president and chief scientific officer. Dr Caldwell was most recently entrepreneur-in-residence at Third Rock Ventures.